Biomarkers market to top $112b by 2031 on drug discovery demand

Consumables held the largest share at 73.4% in 2025.

The global biomarkers market is projected to grow to $112.1b by 2031, from $67.95b in 2026, due to expanding use in drug discovery and clinical trial design, MarketsandMarkets said.

It attributed this to a rise in liquid biopsy and minimally invasive testing, advances in multi-omic panels, artificial intelligence-enabled analysis, and high-throughput automation.

Based on offering, consumables dominated the market in 2025, accounting for 73.4% in revenue, whilst safety biomarkers led by type with a 48.5% share.

Genomics was the largest research area, driven by high-throughput methods such as next-generation sequencing and microarray analysis that enable rapid biomarker discovery and validation.

Meanwhile, next-generation sequencing is projected to post the fastest growth from 2026 to 2031, supporting applications including whole-genome and exome sequencing, gene panels, RNA sequencing, and single-cell analysis.

Regionally, North America held the largest market share in 2025, underpinned by a dense base of biopharmaceutical companies, academic medical centres, and reference laboratories, alongside strict FDA regulation and NIH-backed research funding.

Asia Pacific is seen as the fastest-growing region, expanding at a 12.4% compound annual growth rate over the forecast period.